List of Excipients in Branded Drug KINEVAC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bracco Diagnostics Inc	KINEVAC	sincalide	0270-0556	ARGININE HYDROCHLORIDE	1969-12-31
Bracco Diagnostics Inc	KINEVAC	sincalide	0270-0556	LYSINE HYDROCHLORIDE	1969-12-31
Bracco Diagnostics Inc	KINEVAC	sincalide	0270-0556	MANNITOL	1969-12-31

KINEVAC Excipient Strategy and Commercial Opportunities for Sincalide

Last updated: August 3, 2026

KINEVAC is an injectable sincalide product used primarily to stimulate gallbladder contraction during diagnostic imaging and to support selected gastrointestinal and pancreatic-function studies. Its commercial opportunity is a specialized hospital and imaging-center market rather than a high-volume chronic-care market. The strongest product strategies are ready-to-use delivery, reliable supply, low-volume injectable manufacturing, and excipient-controlled stability.

KINEVAC’s active ingredient is sincalide, a synthetic cholecystokinin analog. The product is supplied as a sterile lyophilized powder for reconstitution in a single-dose vial. The formulation has a narrow dosing range, which makes peptide assay, adsorption control, reconstitution performance, and container compatibility more important than simple tablet-style excipient selection (U.S. Food and Drug Administration [FDA], 2018; DailyMed, 2024).

What is KINEVAC and how is sincalide used?

KINEVAC is an injectable diagnostic agent containing sincalide. It is administered intravenously to induce gallbladder contraction during cholecystography and hepatobiliary imaging procedures. Sincalide can also accelerate intestinal transit and may be used in specialized diagnostic testing involving pancreatic secretion.

KINEVAC product profile

Attribute	KINEVAC profile
Active ingredient	Sincalide
Therapeutic category	Diagnostic gastrointestinal agent
Pharmacologic class	Cholecystokinin analog
Dosage form	Sterile lyophilized powder for injection
Strength	5 micrograms per single-dose vial
Route	Intravenous administration after reconstitution
Primary use	Gallbladder contraction during diagnostic imaging
Commercial setting	Hospitals, radiology departments, imaging centers
Manufacturer historically associated with product	Bracco Diagnostics
FDA pathway	Approved prescription drug product
Product type	Synthetic peptide injectable, not a conventional monoclonal biologic

The product is not a therapeutic drug used continuously by patients. Demand depends on imaging volumes, nuclear medicine protocols, hospital formularies, and availability of alternative diagnostic approaches.

What excipients are used in KINEVAC?

KINEVAC uses a minimal lyophilized injectable formulation. Public labeling identifies mannitol as an inactive ingredient in the vial. Sodium chloride injection is used for reconstitution and administration under the product instructions, but it should be distinguished from the excipients contained in the lyophilized cake (FDA, 2018).

Why mannitol is commercially relevant

Mannitol can perform several functions in a peptide injectable:

• It provides bulking material for a low-dose lyophilized cake.
• It improves cake structure and handling.
• It can influence reconstitution behavior.
• It may help maintain an acceptable appearance after freeze-drying.
• It avoids preservatives in a single-dose intravenous product.

The active drug quantity is measured in micrograms, while the excipient mass is substantially larger. This creates an analytical requirement to demonstrate uniform distribution of sincalide throughout the manufacturing batch. A low-dose peptide product can meet label specifications while still presenting manufacturing risks if the drug substance adsorbs to equipment surfaces, filters, tubing, or the vial.

Excipient strategy for a KINEVAC successor

A follow-on product should initially target the simplest formulation that can demonstrate pharmaceutical equivalence to the reference product. A formulation with the same active ingredient, the same concentration, the same route, a similar lyophilized presentation, and the same principal inactive ingredient would reduce regulatory and technical risk.

Potential excipient options include:

Excipient approach	Commercial benefit	Key technical risk
Mannitol-based lyophilized cake	Closest to the reference formulation; simple regulatory position	May provide limited protection against peptide adsorption or oxidation
Mannitol plus buffering agent	Better pH control during reconstitution	Buffer may alter peptide stability or require additional compatibility work
Trehalose or sucrose system	Potentially stronger peptide stabilization	Greater formulation difference from KINEVAC; new bioequivalence and stability burden
Ready-to-use isotonic solution	Removes reconstitution step	Higher degradation, oxidation, and preservative-free container risks
Prefilled syringe	Reduces preparation errors and nursing time	Device compatibility, silicone oil, extractables, and low-dose adsorption issues
Dual-chamber device	Separates diluent and peptide until use	High device-development and combination-product cost

The best near-term strategy is usually a reference-like lyophilized vial. A ready-to-use product may create more commercial differentiation, but it also introduces greater stability and regulatory risk.

What formulations are protected by KINEVAC patents?

The principal commercial protection for KINEVAC is regulatory and manufacturing know-how rather than a clearly identifiable high-value active patent estate. Sincalide was approved decades ago, and any original composition-of-matter protection would have expired. Public product information does not indicate a current patent barrier that would prevent development of a sincalide injectable with a comparable formulation.

Formulation patent opportunity

A new formulation could support patent protection if it produces a measurable technical advantage, such as:

• Improved long-term stability at refrigerated or controlled-room-temperature storage.
• Reduced aggregation or oxidation of sincalide.
• Faster or more predictable reconstitution.
• Lower adsorption to glass, elastomer, tubing, or syringe components.
• A stable ready-to-use formulation without preservatives.
• A prefilled delivery system with validated dose recovery.
• Reduced preparation time in nuclear medicine or radiology departments.

A patent claim limited to the use of mannitol as a conventional bulking agent would likely face substantial obviousness risk. Stronger claims would require comparative data showing unexpected stability, recovery, or usability advantages over the reference product and routine lyophilized peptide formulations.

When does KINEVAC lose exclusivity?

KINEVAC’s original market exclusivity and any original patent protection have expired. The practical issue is therefore not loss of exclusivity but the difficulty of developing and commercializing a competing sincalide product.

Protection category	KINEVAC assessment
New chemical entity exclusivity	Expired
Original composition patent	Expected to be expired
Pediatric exclusivity	No current commercial significance identified
Orphan exclusivity	Not the principal protection mechanism
Formulation exclusivity	No widely recognized current barrier identified
Method-of-use patents	Any original rights would likely be expired
Regulatory reference-product status	Important for any ANDA or 505(b)(2) strategy
Biosimilar exclusivity	Not applicable in the conventional biologic sense

The commercial opening is therefore available in principle. The development decision depends on market size, manufacturing economics, FDA requirements, and supply reliability.

What is the Orange Book status of KINEVAC?

KINEVAC should be evaluated through the FDA Orange Book and Drugs@FDA records as an approved reference product. The critical diligence questions are whether the product has an active listing, whether any patents are listed, whether the reference product is currently marketed, and whether an ANDA applicant can rely on the product for a 505(j) submission (FDA, 2024a; FDA, 2024b).

Paragraph IV challenge considerations

A generic applicant would use a Paragraph IV certification only if an Orange Book-listed patent remained relevant. Because KINEVAC is an older product, the more likely regulatory issues are:

• Whether the product remains actively marketed as the reference listed drug.
• Whether the proposed generic can demonstrate pharmaceutical equivalence.
• Whether the very low sincalide dose creates content-uniformity concerns.
• Whether the formulation is sufficiently comparable for an ANDA.
• Whether clinical endpoint or pharmacodynamic evidence is required.
• Whether the dosage form and reconstitution process are equivalent.

If the reference product is not actively marketed or the relevant strength is unavailable, a 505(b)(2) application may be more practical than an ANDA. The 505(b)(2) pathway can support reliance on published literature or FDA findings for sincalide while allowing formulation, presentation, or administration differences.

How strong is the KINEVAC patent estate?

The patent estate appears weak as a barrier to entry and potentially more valuable as a freedom-to-operate benchmark. The principal defensible assets for a new entrant would likely be process, formulation, device, and manufacturing patents rather than broad sincalide claims.

Patent-strength assessment

Asset category	Expected strength for KINEVAC	Implication
Sincalide composition patent	Low because of product age	Does not block modern entry
Basic injectable formulation	Low to moderate	Likely vulnerable to obviousness attacks
Lyophilization process	Moderate if supported by comparative data	May protect manufacturing advantages
Container-closure system	Moderate	Relevant to adsorption and stability
Ready-to-use presentation	Moderate to high if technically differentiated	Could support premium positioning
Prefilled syringe device	Moderate	Requires device-specific claims
Manufacturing know-how	Potentially high but non-public	Difficult for competitors to copy directly
Method-of-use claims	Low for legacy diagnostic indications	Original rights likely expired

Patent value will depend on claim scope and data, not on the existence of a new excipient alone. A formulation patent that covers a defined pH range, excipient ratio, moisture limit, peptide concentration, and stability result would be more defensible than a broad claim to “sincalide plus a stabilizer.”

What commercial opportunities exist for KINEVAC competitors?

The market is small but can support focused injectable products where supply interruptions, preparation burden, or hospital procurement friction create value.

1. Generic lyophilized vial

A direct generic could compete on:

• Unit price.
• Back-order prevention.
• Contracting with hospital systems.
• Distribution through radiology and nuclear medicine suppliers.
• Reliable vial availability.
• Simplified reconstitution instructions.

This is the lowest-risk product strategy but also the least differentiated.

2. Ready-to-use sincalide injection

A stable solution could eliminate vial reconstitution and reduce medication-preparation steps. Commercial advantages include lower pharmacy labor, reduced preparation variability, and more predictable workflow in imaging departments.

The formulation must address peptide degradation, microbial control, container adsorption, and dose recovery. A preservative-free single-dose cartridge or syringe would be preferable for intravenous use, but the container system could become the principal development challenge.

3. Prefilled syringe or cartridge

A prefilled presentation could appeal to high-volume imaging centers. The product would need to demonstrate accurate delivery at microgram doses, acceptable syringe hold-up volume, low adsorption, and compatibility with standard administration systems.

The device may qualify as a combination product, increasing development and manufacturing complexity. The commercial case is strongest where procedure time and preparation labor have measurable economic value.

4. Hospital supply and shortage-resilience product

KINEVAC demand is concentrated. A supplier with validated sterile peptide manufacturing and dependable distribution could win share without creating a materially different clinical product.

The opportunity is particularly relevant when there are limited suppliers, intermittent shortages, or hospital requirements for dual sourcing. Manufacturing redundancy, qualified contract manufacturing, and a stable raw-material supply chain may be more valuable than an aggressive patent program.

5. Geographic licensing

A regional licensing strategy could target:

• North American hospital injectables.
• European diagnostic imaging markets.
• Asian radiology and nuclear medicine distributors.
• Contract manufacturers with local sterile-filling capacity.

A license should distinguish rights to the sincalide drug substance, the finished dosage form, the device, and the manufacturing process. Territorial rights may be practical because diagnostic protocols, reimbursement, product registration, and distribution channels differ by country.

Which companies are challenging KINEVAC?

Publicly visible competition is more likely to come from alternative diagnostic protocols and hospital-supplied products than from multiple branded sincalide competitors. The relevant competitive groups are:

1. The KINEVAC reference-product supplier.
2. Potential generic injectable manufacturers.
3. Contract manufacturers with sterile lyophilization and peptide capabilities.
4. Imaging providers using alternative gallbladder stimulation protocols.
5. Suppliers of related diagnostic agents and radiopharmaceutical workflow products.

The absence of a large branded competitor does not eliminate commercial risk. A generic entrant may face limited market share because the reference product is familiar to imaging departments and because physicians may not switch products unless supply or price improves.

What patent litigation and settlement risks affect KINEVAC?

No major, widely reported current patent litigation campaign is associated with KINEVAC’s legacy product. The litigation risk for a new entrant would instead arise from:

• Orange Book patent certification disputes.
• Formulation or device patent claims filed by a newer supplier.
• Trade-secret allegations involving lyophilization or peptide handling.
• Contract-manufacturing disputes.
• Patent claims covering a ready-to-use formulation.
• Regulatory exclusivity disputes if a new clinical indication is approved.

A Paragraph IV settlement would be relevant only if an active Orange Book-listed patent existed. For an older sincalide product, the greater strategic risk is a later-filed formulation or device patent that delays a differentiated launch even though the basic active ingredient is unprotected.

What FDA regulatory pathway applies to a KINEVAC follow-on?

A direct equivalent would generally target an ANDA if the reference listed drug, dosage form, strength, route, and formulation support pharmaceutical-equivalence and bioequivalence findings. A product with a new excipient system, new device, ready-to-use solution, or materially different presentation may require a 505(b)(2) application.

Regulatory development priorities

The sponsor would need to establish:

• Identity, strength, quality, purity, and potency of sincalide.
• Peptide content uniformity at microgram-scale dosing.
• Sterility and bacterial endotoxin control.
• Reconstitution time and completeness.
• Stability under labeled storage conditions.
• Container-closure integrity.
• Compatibility with diluents, syringes, needles, and infusion tubing.
• Absence of clinically meaningful differences in pharmacologic effect.
• Consistency of gallbladder contraction or another accepted pharmacodynamic endpoint where required.

Sincalide is not an interchangeable biosimilar candidate in the usual monoclonal-antibody sense. It is a synthetic peptide product whose regulatory classification may depend on the proposed route, formulation, manufacturing process, and reference-product relationship.

How does KINEVAC compare with competing drug opportunities?

Opportunity	Market size	Formulation difficulty	Patent potential	Commercial attractiveness
Direct sincalide generic	Small	Moderate	Low	Moderate for focused injectable firms
Ready-to-use sincalide	Small	High	Moderate to high	Moderate to strong if workflow savings are proven
Prefilled sincalide device	Small	High	Moderate	Selective
Broader diagnostic peptide portfolio	Larger	High	Higher	Stronger platform economics
Chronic peptide therapy	Much larger	High	High	Greater investment and clinical risk

KINEVAC is most attractive as part of a broader sterile injectable or diagnostic-peptide portfolio. As a standalone product, revenue potential is constrained by procedure volume and limited repeat use.

What generic launch scenarios exist for KINEVAC?

Scenario 1: Price-led vial launch

A sponsor launches a reference-like lyophilized vial after demonstrating equivalence. This scenario requires the least commercial differentiation and depends on low-cost sterile manufacturing and hospital contracting.

Scenario 2: Supply-led launch

A sponsor positions the product as a reliable second source. The value proposition centers on inventory continuity, dual manufacturing sites, and dependable wholesaler supply.

Scenario 3: Workflow-led launch

A sponsor introduces a ready-to-use syringe or solution. The product seeks a premium based on reduced preparation time, lower handling risk, and improved imaging workflow.

Scenario 4: Portfolio-led launch

A supplier combines sincalide with other diagnostic injectables, radiology products, or nuclear medicine agents. Shared sales channels and manufacturing infrastructure improve economics.

What revenue exposure does KINEVAC create?

KINEVAC revenue is exposed to diagnostic imaging volume, hospital purchasing, supply interruptions, reimbursement policies, and the availability of alternative procedures. It is less exposed to chronic prescription adherence or retail pharmacy substitution.

The product’s low dose does not necessarily produce low manufacturing cost. Sterile filling, lyophilization, quality testing, peptide recovery, and release controls can dominate cost of goods. A small market can remain profitable if the product has limited competition and the supplier uses existing injectable infrastructure.

Key Takeaways

• KINEVAC contains sincalide, a synthetic cholecystokinin analog used mainly in diagnostic imaging.
• The product is a low-dose, single-use lyophilized injectable with a minimal excipient system.
• Mannitol is identified in public labeling as an inactive ingredient in the lyophilized product.
• Original active-ingredient and legacy exclusivity barriers are no longer the primary obstacle to entry.
• The strongest follow-on opportunity is a reference-like generic supported by reliable supply.
• The strongest differentiated opportunity is a ready-to-use or prefilled presentation.
• A new excipient patent requires comparative stability, recovery, or usability data.
• FDA pathway selection depends on whether the product is formulation-equivalent or materially different.
• Biosimilar strategy is generally not the relevant framework for this synthetic peptide.
• Commercial value is likely highest within a broader sterile injectable or diagnostic-drug portfolio.

FAQs About KINEVAC Excipient and Commercial Strategy

Is mannitol the main excipient in KINEVAC?

Public product labeling identifies mannitol as an inactive ingredient in the lyophilized vial. Sodium chloride injection is used for reconstitution according to product instructions.

Can a company develop a generic KINEVAC without a new clinical trial?

A direct ANDA may avoid a conventional efficacy trial if the applicant demonstrates pharmaceutical equivalence and satisfies FDA bioequivalence and quality requirements. A materially different formulation may require a 505(b)(2) application and additional evidence.

Would a ready-to-use sincalide injection be patentable?

It could be patentable if the formulation provides a non-obvious stability, dose-recovery, container-compatibility, or usability advantage. A simple liquid version without supporting technical data would face greater patent risk.

Is KINEVAC exposed to biosimilar competition?

Conventional biosimilar competition is not the main issue. Sincalide is a synthetic peptide diagnostic product, so generic or 505(b)(2) competition is more relevant.

What is the best commercial strategy for a KINEVAC competitor?

The most practical strategy is a reliable, reference-like sterile vial supported by hospital contracts. A ready-to-use syringe offers greater differentiation but requires more complex formulation, device, stability, and regulatory development.

References

DailyMed. (2024). Kinevac: Sincalide injection, powder, lyophilized, for solution. U.S. National Library of Medicine.

U.S. Food and Drug Administration. (2018). Kinevac (sincalide) prescribing information. Bracco Diagnostics Inc.

U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov

U.S. Food and Drug Administration. (2024b). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/